Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: The analysis suggests the potentially harmful effect of Celebrex dosage is most pronounced in higher-risk patients, researchers said at the American College of Cardiology scientific meeting. “Patients at low cardiovascular risk should take some level of comfort,” said Dr. Scott Solomon, lead researcher of the National Cancer Institute-sponsored analysis. “That wasn’t so clear previously.”   Doctors should exercise caution in prescribing the drug, generally known as celecoxib, in high-risk patients, said Solomon, whose analysis was also published online in the journal Circulation. Celebrex belongs to a class of pain drugs known as cox-2 inhibitors and is the only such drug still on the market in the United States. Merck and Co Inc withdrew its widely used cox-2 drug, Vioxx, from the market in 2004 after a study showed it doubled the risk of heart attack and stroke in long- term users. Another cox-2 inhibitor from Pfizer called Bextra was also pulled from the U.S. market due to safety concerns. While the analysis sheds light on how the drug should be used, Solomon said he could not judge whether the data lift the cloud over this class of drugs. The six trials involving a total of 7,950 patients all studied Celebrex against a placebo for uses other than arthritis. Patients received either 400 milligrams once a day, 200 mg twice a day, or 400 mg twice a day. The primary goal of the pooled analysis was an assessment of the combined risk of cardiovascular death, heart attack, stroke, heart failure or events involving blood clots. Researchers found the heart risk was lowest at the 400 mg daily dose. They found nearly a two-fold risk of adverse heart events with the 200 mg twice daily dose and that jumped to about a three-fold risk at the 400 mg twice daily dose. “Even 400 mg once a day showed elevated risk” in the high-risk population, Solomon said, adding he could not extrapolate whether doses lower than 400 mg cut risk further. The increased risk was not affected by aspirin use, researchers said. “Most of the data used in this pooled analysis have previously been published and are consistent with what we already know about the cardiovascular risks of Celebrex and other prescription arthritis pain relievers,” said Gail Cawkwell, Pfizer’s executive medical director. “The analysis doesn’t provide any new conclusions on the FDA-approved doses of Celebrex, including the most commonly prescribed dose of 200 mg daily,” she said. Dr. Steven Nissen of the Cleveland Clinic, who has a study on lower doses underway, added: “There aren’t long-term randomized placebo-controlled trials for that dose, The only way we’re ever going to answer these questions is with good randomized prospective data,” he said. “We’ll tell it like it is when the data is in.” Claim: Celebrex risky in high-risk patients, study finds.
Example Output: Doctors should prescribe the lowest doses of Celebrex possible in patients at high risk of heart problems, researchers who did a combined analysis of six studies of the Pfizer Inc pain drug said on Monday.

Example Input: Paragraph: There is also the revival of the humble foam roller, which experts say, like old-time push-ups, squats and planks, has never been more popular. Anita Golden, fitness manager at a Crunch gym in New York City, said she’ll be giving clients a foam roller called the GRID. “We’ve always had foam rollers in the club but now more people are using them as a way to ease post-workout muscles, prevent injuries and exercise the core,” Golden said. When it comes to big-ticket items, Colleen Logan of Icon Health and Fitness, which manufactures a number of fitness brands, said the treadmill remains the most popular gift. “Treadmills continue to lead the industry in terms of home fitness purchases,” said Logan. They account for about 57 percent of fitness purchases, while elliptical trainers and stationary bicycles are a distant second and third place at about 8 percent each. The average home treadmill costs about $700, said Logan, but the technology revolution has transformed even this stalwart at the high end. The ultimate splurge, at $4,000, she said, is the Boston Marathon Treadmill, which allows users to adjust speed in 1/10 of a mile per hour increments without touching the console. It also lets users run a virtual Boston Marathon. For people on a smaller budget, there is the iFit app that lets the iPhone capture a favorite vacation run or bike ride in Hawaii, store it in data centers all over the world which collectively are referred to as the “cloud,” and download it to an iFit-enabled treadmill at home. “You’ll view the exact route and experience the same terrain again,” Logan explained. Devices, gadgets and apps proliferate as tech-savvy fitness becomes more accessible, according to Jessica Matthews of the American Council on Exercise (ACE). “There’s a lot of interest in on-body monitoring devices as ways to motivate and track progress,” she said. “They run the gamut from basic devices to track hours, steps, and caloric expenditure to full-body tracking.”  Nike+ Sportsband has a series of small lights on the wrist band that change from red to green as the runner nears his goal, while the BodyMedia FIT Armband tracks everything from the number of calories burned to the quality and quantity of sleep. ACE also studied fitness DVDs released for the holidays. “We evaluated them for quality of instruction, safety, effectiveness and design of workout,” Matthews said. Among the best were “Amy Dixon’s Breathless Body Vol.2: The Edge.” Matthews called it a challenging cardio workout best suited to those on your list with “an established base of fitness.”  “Jessica Smith’s 10 Pounds Down Better Body Blast” also got a thumbs up for its well-rounded routine and clarity of instruction. For people seeking a mind-body approach, Matthews praised “STOTT Pilates Intense Body Blast: Pilates Interval Training: Level I,” which she said is accessible for someone new to fitness. “They do a great job queuing movements and creating flow,” she said. Richard Cotton of the American College of Sports Medicine suggests giving the fitness novice the gift of a personal trainer. “The best is human assistance,” he said. “Another way is a beginner group exercise class.”  He also suggests a gift certificate for shoes at a running store equipped with a treadmill. “You need shoes that fit your gait,” he said. “People should always get their gait analyzed.”  Golden likes to cite the law of reciprocity to the personal trainers she manages. “I always tell them to get their clients something,” she said. And what does the personal trainer want for Christmas? “I like the roller, or a new jump rope,” she said. “Fitness people aren’t hard to please. Get me a new yoga mat and I’m happy.” Claim: Holiday fitness gifts trend from high-tech to basic.
Example Output: Looking for the perfect holiday present for a fitness fan? Gift offerings this year range from apps that can store a run in the country to be viewed later to gadgets so sophisticated they measure quality of sleep as well as calories burned.

Example Input: Paragraph: In a “complete response letter” to Amag, the FDA suggested that the company generate additional safety data for the wider patient population and evaluate the dosing or administration of the drug, Feraheme. “The FDA did propose that the company conduct additional trials,” Amag Chief Executive William Heiden told Reuters. “We do have existing safety data from our two large late-stage trials ... certainly we would look to that data to support the safety profile of Feraheme.”  The FDA asked Amag to provide additional safety data related to serious hypersensitivity, cardiovascular events and deaths. Heiden said conducting a new study with safety as the main goal would be easier than conducting an efficacy study, adding that Amag could begin a trial this year, if it came to an agreement with the FDA. “The treatment period is fairly short and there’s a fairly short followup,” he said. “The size of the trial and enrolment would be the determining factor on how long the trial would run.”  This is not the first time Amag has faced problems related to Feraheme, which is marketed as Rienso in Europe. Last May, one of Amag’s partners, Takeda Pharmaceutical Co Ltd, recalled a batch of Rienso because of a death and several cases of hypersensitivity. In one of the late-stage trials conducted for the drug’s wider approval, Amag reported three deaths, of which two were in the Feraheme-controlled group, but none related to the drug. The regulator said the company had not provided enough information for the FDA to label the drug as safe for use in patients with adult iron deficiency anemia (IDA) who have failed or cannot tolerate oral iron treatment. The drug, Feraheme, is already approved to treat iron deficiency anemia in adult chronic kidney disease patients. Amag’s shares were down about 8 percent at $20.14 in morning trading on the Nasdaq. Claim: FDA rejects wider use of Amag anemia drug; shares slide.
Example Output:
Amag Pharmaceuticals Inc said the U.S. Food and Drug Administration rejected its application for wider use of its iron deficiency drug due to safety concerns and asked for more trial data, sending its shares down as much as 15 percent.